{"id":"c70d2dc0-770a-5e01-ba81-0aff864d5f28","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-escherichia-increase","predicate":"increases","statement":"A relative increase in the abundance of Escherichia species was proposed as a microbiota-mediated mechanism behind the known intestinal adverse effects of metformin.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"65b53106-ba00-5274-9a10-91421c78b6fd","mechanism_event_label":"The same shift may explain why the drug upsets some people’s gut.","subject":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"object":{"id":"f8ac391f-c457-50ca-8507-234ff2ae67fa","slug":"escherichia-species","display_name":"Escherichia species in the gut metagenome","entity_type_key":"organism"},"evidence_count":1,"mechanism_event":{"id":"65b53106-ba00-5274-9a10-91421c78b6fd","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-escherichia-increase-event","event_type":"observed_intervention","label":"The same shift may explain why the drug upsets some people’s gut.","description":"A relative increase in the abundance of Escherichia species was proposed as a microbiota-mediated mechanism behind the known intestinal adverse effects of metformin.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6286aae7-664f-569f-b4fa-3e9fe70d666c","slug":"metformin-gastrointestinal-intolerance","display_name":"Gastrointestinal intolerance of metformin","entity_type_key":"cellular_process"},"role":"proposed_outcome","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f8ac391f-c457-50ca-8507-234ff2ae67fa","slug":"escherichia-species","display_name":"Escherichia species in the gut metagenome","entity_type_key":"organism"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/metformin-research/26633628.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f83ac1daddf6372ef8d16d3944ed9b6d62f0d1c12fb5815fb7c27cda2244f984\", \"start_char\": 0, \"end_char\": 1570, \"text_sha256\": \"f83ac1daddf6372ef8d16d3944ed9b6d62f0d1c12fb5815fb7c27cda2244f984\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Reanalysis of 784 human gut metagenomes stratified by treatment","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Metformin treatment as a confounder in type 2 diabetes metagenomes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"An observational reanalysis. It separates disease signature from drug signature; it does not measure a clinical outcome. A corrigendum was issued for this paper (Nature 2017;545:116, PMID 28470190); its notice body was not available, so its impact on these records has not been assessed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"metformin","display_name":"Metformin","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same shift may explain why the drug upsets some people’s gut.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[metformin-p26633628] Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. (2015). https://pubmed.ncbi.nlm.nih.gov/26633628/ DOI: 10.1038/nature15766","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Gut microbiome","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"dfcacf61-4132-56b7-a577-2c59a68ad4e0","evidence_kind":"source_excerpt","locator":"Lines 957-968","start_line":957,"end_line":968,"excerpt":"### metformin-escherichia-increase\nA relative increase in the abundance of Escherichia species was proposed as a microbiota-mediated mechanism behind the known intestinal adverse effects of metformin.\nCondition category: normal\nnutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.\nplain_language: The same shift may explain why the drug upsets some people’s gut.\norganism: Human\ntissue_or_cell_type: Gut microbiome\nexperimental_model: Reanalysis of 784 human gut metagenomes stratified by treatment\nlimitations: An observational reanalysis. It separates disease signature from drug signature; it does not measure a clinical outcome. A corrigendum was issued for this paper (Nature 2017;545:116, PMID 28470190); its notice body was not available, so its impact on these records has not been assessed.\nexposure: Metformin treatment as a confounder in type 2 diabetes metagenomes\nevidence_span: {\"source_cache\": \"artifacts/metformin-research/26633628.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f83ac1daddf6372ef8d16d3944ed9b6d62f0d1c12fb5815fb7c27cda2244f984\", \"start_char\": 0, \"end_char\": 1570, \"text_sha256\": \"f83ac1daddf6372ef8d16d3944ed9b6d62f0d1c12fb5815fb7c27cda2244f984\"}\n[metformin-p26633628] Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. (2015). https://pubmed.ncbi.nlm.nih.gov/26633628/ DOI: 10.1038/nature15766","model_system":"Reanalysis of 784 human gut metagenomes stratified by treatment","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [metformin-p26633628] Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. (2015). https://pubmed.ncbi.nlm.nih.gov/26633628/ DOI: 10.1038/nature15766","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d0474bd9-7cfd-5695-a152-12f3633a6813","stable_key":"import-8b3cf083-ea9c-54f5-b42b-bf1fef5b2978","title":"Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0b51d0759aeeb88ac5b3a6277245a196b2bb024d7c32ec89379ed428fb06bfb5","revision_id":"0405c75e-f06e-5af7-a642-1777802f6004","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}